## PRISM MEDICO AND PHARMACY LIMITED

CIN: L51109HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Date: 14.08.2022

| To,  | То,   |
|--|---|
| Department of Corporate Services,<br>BSE LIMITED | Listing Department,<br>Metropolitan Stock Exchange of India Limited |
| P. J. Towers, Dalal Street,                      | (MSEI)  |
| Mumbai, Maharashta-400 001.                      | Vibgyor Towers, 4th Floor,  |
|  | Plot Number C 62, G - Block,  |
|  | Opposite Trident Hotel,   |
|  | Bandra Kurla Complex,   |
| ISIN : INE730E01016                              | Bandra (E), Mumbai, Maharashtra–400098.                             |
| Scrip Code: 512217                               | SYMBOL: PRISMMEDI   |

Subject: Clarification/Resubmission - Outcome of Board Meeting held on 13th August, 2022.

Dear Sir / Madam,

With reference to the above captioned subject, it is hereby submitted that due to the inadvertent mistake/oversight, the financial details relating to the previous quarters ended 30<sup>th</sup> June, 2021 and 31<sup>st</sup> March, 2022 and current quarter ended 30<sup>th</sup> June, 2022 (other equity) could not be correctly filled in by the data entry operator. We really regret for furnishing the said details and now to set the records right, we enclose herewith the financial results after removing the typographical errors.

Kindly acknowledge the receipt and oblige.

Thanking You, Yours Truly, FOR PRISM MEDICO AND PHARMACY LIMITED.

11

DAVENDER SINGH DIRECTOR DIN: 09447213.

| PRISM MEDICO AND PHARMACY LTD.<br>CIN : L51109HP2002PLC009299<br>STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022 (In Lakhs) |  |                  |                  |             |                         |              |                          |  |  |
|--|--|------------------|------------------|-------------|-------------------------|--------------|--------------------------|--|--|
|  |  |                  |                  |             |                         |              |                          |  |  |
|  |  | 30.06.2022       | 31.03.2022       | 30.06.2021  | Year to date 30.06.2022 | 31.03.2022   | 31.03.2021               |  |  |
| I  | Income<br>Revenue from operations<br>Other income  | -                | 844.38           | -           | -                       | 844.38       | 1,676.35                 |  |  |
|  | Total income from operations   | -                | 844.38           | -           | -                       | 844.38       | 1,676.35                 |  |  |
| п  | Expenses   |                  |                  |             |                         |              |                          |  |  |
|  | Cost of Material Consumed  | -                | -<br>1,055.18    | -           | -                       | -<br>1055.18 | 2146.7                   |  |  |
|  | Change In Inventories  | -                | (192.39)         | -           | -                       | (192.39)     | -479.9                   |  |  |
|  | Employee benefit expenses  | 3.01             | 5.59             | -           | 3.01                    | 19.04        | 16.76                    |  |  |
|  | Finance costs  | -                | 0.04             | -           | -                       | 0.04         | 0.02463                  |  |  |
|  | Depreciation and amortization expenses   | -                | 0.17             | 0.23        | -                       | 0.86         | 1.2                      |  |  |
|  | Other expenses   | 4.73             | 3.67             | 5.22        | 4.73                    | 11.55        | 9.04                     |  |  |
|  | Total expenses   | 7.74             | 872.26           | 5.45        | 7.74                    | 894.28       | 1,693.86                 |  |  |
| ш  | Profit/(Loss) before exceptional items and tax   | (7.74)           | (27.88)          | (5.45)      | (7.74)                  | (49.90)      | (17.51                   |  |  |
| IV   | Exceptional items  |                  |                  |             |                         |              | (1                       |  |  |
| v  | Profit/(Loss) before tax   | (7.74)           | (27.88)          | (5.45)      | (7.74)                  | ) (49.90)    | (17.51                   |  |  |
| VI   | Tax expenses<br>a) Current tax<br>b) Deferred tax  | -<br>0.000       | 12.996           | -<br>0.0346 | 0.000                   | ) 12.90      | 4.51                     |  |  |
| VII  | b) Mat Credit<br>Net Profit/(Loss) for the period/year   | (7.74)           | (14.89)          | (5.48)      | (7.74                   | ) (37.00)    | (13.00                   |  |  |
|  | Other comprehensive income (net of tax)<br>Items that will not be reclassified to profit or loss:<br>i) Remeasurement of post employment benefit obligations<br>ii) Income-tax relating to tems that will not be reclassified t<br>oprofit or loss<br>Total other comprehensive income | -                | -                | -           | ۵<br>-<br>-             | -            | -                        |  |  |
| IX   | Total comprehensive income for the period/year (VII+VIII)  | (7.74)           | (14.89)          | (5.48)      | (7.74                   | ) (37.00)    | (13.00                   |  |  |
| x  | Paid-up equity share capital (face value of the share shall be indicated)  | 606.34           | 606.34           | 606.34      | 606.34                  |              | <b>606.3</b> 4<br>686.25 |  |  |
| XI   | Other equity (excluding revaluation reserve)   | 641.39           | 649.13           | 680.77      | 641.39                  | 649.13       | 080.2.                   |  |  |
| XII  | EPS in Rs. (Face Value of Rs.10/- each)*<br>-Basic<br>-Diluted   | (0.01)<br>(0.01) | (0.02)<br>(0.02) |             | (0.01<br>(0.01          | · · · · ·    |                          |  |  |

#### Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 13.08.2022 after being reviewed by the Audit Committee.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the company.

### FOR AND ON BEHALF OF THE BOARD PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH DIRECTOR DIN: 09447213

Place: KALA AMB, HIMACHAL PRADESH. Date: 13.08.2022



# Harjeet Parvesh & Company CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

### Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh - 173030 for the Quarter ended 30th June 2022 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (' Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For HarjeetParvesh & Co. Chartered Accountants

leet Singh 0 095466 te: 13.08.2022



House No. 1122, Sector 71, Mohali Mobile : 096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com

### Scanned by Scanner Go